Updated 08:09 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,859.70 -0.68% CL 88.67 +0.12% BTC 64,634.95 -1.03%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,860 −0.68% BTC $64,635 −1.03% VIX 19.30 +3.21% latest tape · as of 08:09 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic

Scynexis Inc

SCYX · NASDAQ · USD · Market cap $339M · 18 employees

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.

FAIL · Does not pass the screen
3.21 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.21 USD at the 13 Nov 2026 close
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Markdown ?
Screened · screened 2026-11-13
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price3.21 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Markdown3.77-14.9% to today ✓Distribution gives way to Markdown after a 15% slide in 4 weeks
2026-10-02Read Distribution4.46-28.0% to today ✓Markdown gives way to Distribution first Distribution read since July
2026-09-12Read Markdown4.27-24.8% to today ✓Markup gives way to Markdown
2026-08-12Read Markup4.27-24.8% to today Distribution gives way to Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Scynexis Inc holds its Markdown at $3.21. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-13
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$3.21
ValuationN/A trailing · -1.69 forward price to earnings
Values screenFAIL · score 70.0
Beta1.10
The Workings

Five Screens, Shown in Full

Does not pass. Revenue purity

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 3.68% Below 33% Interest-bearing debt is just 3.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 31.80% Below 33% Cash held in interest-bearing accounts and securities is 31.8% of assets, under the one-third limit. Pass
Receivables 36.02% Below 49% Money owed to the company is 36.0% of assets, under the 49% limit. Pass
Revenue purity 10.57% Below 5% 10.6% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Scynexis clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 11% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when SCYX's ethical verdict changes

Today SCYX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
24.00Street low 32.00Street average 44.64Street high 3.21Price

Third-party analyst targets. The average target sits +897% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-1.7x
EPS, trailing-3.84
EPS, forward-2.52
Profit margin-120.5%currently unprofitable
Return on equity-53.4%not currently earning a positive return on equity
FCF yield0.71%
Debt to equity4.99heavy leverage: higher risk if revenue softens
Current ratio3.94comfortably covers its short-term bills
Beta1.10moves a little more than the market
Short interest, float0.04%
52-week range3.68 - 10.48
MoatNONE
Market cap$339M
Employees18

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

SCYX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-13 Markdown $3.33 -11.7% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-11-01 Markdown · changed $3.77 -4.8% Entry 8

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-10-22 Distribution $3.96 -11.2% Entry 7

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-10-02 Distribution · changed $4.46 +4.4% Entry 6

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-09-12 Markdown · changed $4.27 +0.0% Entry 5

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-08-12 Markup · changed $4.27 +0.9% Entry 4

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-07-18 Distribution $4.23 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (3 analysts) rates it none, with a mean price target of $34.

2026-07-03 Distribution $4.23 +0.0% Entry 2

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Distribution $4.23 Entry 1

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in SCYX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.59 -37.0% · $630 -37.0%
2 months $8.00 -48.1% · $519 -48.1%
3 months $7.12 -41.7% · $583 -41.7%
6 months $5.16 -19.6% · $804 -19.6%
1 year $7.06 -41.2% · $588 -41.2%
2 years $16.56 -74.9% · $251 -74.9%
3 years $22.08 -81.2% · $188 -81.2%
5 years $64.96 -93.6% · $64 -93.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SCYX does next, these words stay.

Scynexis Inc · SCYX · Markdown · $3.21
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.